Effects of simvastatin on lipid profile, atherogenic index and serum transaminases in hyperlipidemic patients

  • Showan D. Husain Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
  • Ari Aziz Salih Department of Medical Supply, Ministry of Health, Kurdistan Region, Erbil, Iraq.
Keywords: Hyperlipidaemia, simvastatin, lipid profile, atherogenic index

Abstract

Background and objectives: Hyperlipidemia is characterized by increased concentrations of lipids including triglycerides, total cholesterol, low density lipoproteins, very low density lipoproteins in the blood and some times decreased high density lipoproteins .

Many drugs have been used for treatment of this disorder. The present study was designed to estimate the effects of simvastatin on lipid profile, atherogenic index, transaminases, creatinine, uric acid and alkaline phosphatase.

Methods: This study covered 70 subjects, they were divided into two groups, the first group included 45 hyperlipidaemic patients which were treated with 20mg simvastatin and second group included 25 normal subjects. After 12 hours fasting, serum lipid profile, transaminases; alkaline phosphatase, uric acid and creatinine were measured for the patients in 3 intervals before treatment, after 8 weeks and 16 weeks of treatment, and one time for normal subjects.

Results: : After therapy, simvastatin showed a significant reduction in serum (TC, TG, LDL, VLDL and atherogenic index) and also, significant rise in HDL noticed, by performing a comparison between the group before treatment, and groups after treatment.Serum ALT, AST and ALP were significantly increased but were still within normal levels.Insignificant effect was observed from serum creatinine, uric acid and also body mass index by performing a comparison between group before treatment and groups after treatment.

Conclusions:Simvastatin was effective in controlling lipid profile and atherogenic index, with no significant abnormality in liver functions.

References

- Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 1998;82(4B):3J-10J.

Jochen K, Jean-Paul T, Bozidar V. Textbook of clinical pharmacology.1st ed. New York : McGraw-Hill; 2000:700-14.

National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults executive summary of the third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III ). JAMA2004; 285: 2486–97

Kasper D,Braunwald E,Hauser S,Longo D,Fauci A. Harrison's principles of internal medicine;16th ed. New York: McGraw-Hill professional; 2004: 2293-8.

Katzung B.G. Textbook of basic and clinical pharmacology.10thed. Online edition electronic book. 2007.

Blum C. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994; 73 Suppl D: 3-11.

Mycek J, Harvey A, Champe C, Fisher D. Lippincott's illustrated reviews: Pharmacology 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000: 207-15.

Daniel W.W. Biostatistics: A foundation for analysis in the health science.3rd ed, New York: John Wiley and Sons;1983;134: 206–24.

Ballantyne CM: Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998;82:3Q-12Q.

Bilheimer D, Grundy S, Brown M, Goldstein J. Mevinolin and colestipol stimulate receptor-mediated clearance of low-density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci 1983;80: 4124–8 .

Schaefer E, McNamara JR, Tayler T,Daly J, Gleason J. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 2004;93:31-9.

Wierzbicki A, Lumb P, Semra Y, Chik G, Christ E . Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. Q J Med 1999;92: 387-94.

Santosh S, Pawan K . Effect of simvastatin and atorvastatin on coenzyme Q10. The Internet Journal of Cardiology 2007; 4 (1).

Antti J, Jukka M, Risto H, Arja V, Merja R . Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men. JAMA 2002; 287: 598-605.

Osamu N, Masatoshi M, Motoshige M, Takahiro N, Iwao N . Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int 1999;56: 219–21.

William L, John M, Bruce W, William S. The effect of high dose simvastatin on triglyceride rich lipoprotein metabolism in patients with type 2 diabetes mellitus. J Lipid Res 2006;47: 193-200.

Peter J, Stephanie K, Irene L, Donald H. Comparative dose efficacy study of atorvastatin versus simvastatin, paravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia( The curves study).Am J Cardiol 1998;81:582-7 .

Branchi A, Fiorenza A, Torri A, Muzio F, Rovellini A. Effects of atorvastatin 10mg and simvastatin 20mg on serum triglyceride levels in patients with hypercholesterolemia. Curr Therap Res 2001;8: 405-15.

Fernando C, Ana C, Juan F, Jose P, Garcia O. Comparison of the hypolipidemic effect of gimfibrozil versus simvavtatin in patients with type III hyperlipoproteinemia. Medscape Am J 1999; 138 (1):156-62.

Abdul-Basit A, Humaira R, Zafar H, Rubina H,Yakoob A. The effect of simvastatin on diabetic dyslipidemia. Journal of Baqai Medical University. 2001; 2 :6-8.

Emel A, Banu N, Canan O, Sema G and Sezer C. The Effect of simvastatin treatment on plasma ubiquinone, blood ATP concentrations, total antioxidant capacity and muscle related markers. Turk J Med Sci 2002;32:323-8.

Kubota T, Fujisaki K, Itoh Y, Yano T, Sendo T. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem. Pharmacol.2004; 67:2175-86.

Scott R, Lintott C, Wilson M. Simvastatin and side effects. N Z Med 1991; 104:493-5.

Darioli R, Bovet P, Brunner HR, Bercher L. Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolaemia. Schweiz. Med. Wochenschr 1990; 120:85-91.

Zena A., Isam M .Comparative effects of lovastatin and simvastatin on liver function tests in hyperlipidemic patients. The Medical Journal of Basrah University 2007;25(1):20-4.

Jyh-Gang L, Mei-Mei H, Wey-Wen J and Jung-Kuei P. Efficacy and safety of 20 mg/day simvastatin in patients with renal impairment and combined hyperlipidemia. FJJM 2005; 3(1):51-5

Haralampos J, Anna I, Sofia G, Vasilios G, Eleni T. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Medscape Am Heart J 2004; 148(4):635-40.

Published
2018-10-22
How to Cite
Husain, S., & Salih, A. (2018). Effects of simvastatin on lipid profile, atherogenic index and serum transaminases in hyperlipidemic patients. Zanco Journal of Medical Sciences (Zanco J Med Sci), 15(2), 29-33. Retrieved from https://zjms.hmu.edu.krd/index.php/zjms/article/view/439
Section
Original Articles